Mechanisms of Action of Mycophenolic Acid

Annals of the New York Academy of Sciences

Volumn 696, Issue 1, 1993, Pages 63-87

  ALLISON, ANTHONY C ^a   KOWALSKI, W JOSEPH ^a   MULLER, CHRISTIAN D ^a   EUGUI, ELSIE M ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CELL NUCLEUS ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DEOXYGUANOSINE TRIPHOSPHATE; DOLICHOL PHOSPHATE; FUCOSE; GLYCOPROTEIN; GUANOSINE PHOSPHATE; GUANOSINE TRIPHOSPHATE; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 2; MANNOSE; MEMBRANE PROTEIN; MERCAPTOPURINE; METHOTREXATE; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROSTAGLANDIN SYNTHASE INHIBITOR; RIBOSEPHOSPHATE PYROPHOSPHOKINASE; SELECTIN; STEROID; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTERY MUSCLE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSTASIS; DISEASE PREDISPOSITION; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EPSTEIN BARR VIRUS; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER INJURY; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; LYMPHOMA; MAINTENANCE THERAPY; MONOCYTE; MOUSE; MULTICENTER STUDY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PURINE SYNTHESIS; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALIA; HUMAN HERPESVIRUS 4;

EID: 0027771740     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1993.tb17143.x     Document Type: Article

References (63)

1. Treatment of cyclophosphamide‐induced hemorrhagic cystitis with intravesical carboprost tromethamine
2. Cyclosporine nephrotoxicity
3. The pharmacology and clinical use of methotrexate
4. Tumors of the immunocompromised patient
5. Malignancy following treatment of rheumatoid arthritis with cyclophospnamide: a long‐term case‐control follow‐up study
6. T‐cell‐mediated regression of spontaneous” and Epstein‐Barr virus‐induced B‐cell transformation in vitro: studies with cyclosporin
7. How one thing has led to another
8. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation
9. The purine path to chemotherapy
10. In vitro DNA cross‐linking by cyclophosphamide: comparison of human chronic lymphocytic leukemia cells with mouse L1210 leukemia and normal bone marrow cells
11. Organ specific activation of azathioprine in mice: role of liver metabolism in mutation induction
12. Inhibition of in vitro vascular endothelial cell proliferation and in vivo vascularization by low‐dose methotrexate
13. Biosynthesis of nucleotides
14. Control of phosphoribosyl pyrophosphate synthesis in human lymphocytes
15. Adenosine deaminase deficiency of two patients with severely impaired cellular immunity
16. Immunological observations on patients with the Lesch‐Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation
17. The role of de novo purine synthesis in lymphocyte transformation
18. Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation of lymphocytes
19. Purine metabolism and control of cell proliferation
20. Effects of adenosine and deoxyadenosine on PHA‐stimulation of lymphocytes of man, horse and pig
21. Failure of dideoxynucleosides to inhibit HIV replication in cultured human macrophages
22. The inhibition of nucleic acid synthesis by mycophenolic acid
23. Bioavailability improvement of mycophenolic acid through amino ester derivitization
24. Lymphocyte‐selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion
25. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug. RS‐16443
26. Comparison of the effects of mizoribine with those of azathioprine, 6‐mercaptopurine, and mycophenolic acid on T‐lymphocyte proliferation and purine ribonucleotide metabolism
27. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins
28. Selectins: interpreters of cell‐specific carbohydrate information during inflammation
29. Cotransfection of ICAM‐1 and HLA‐DR reconstitutes human antigen‐presenting function in mouse L cells
30. Downregulation of cell adhesion molecules LFA‐3 and ICAM‐1 in Epstein‐Barr virus‐positive Burkitt's lymphoma underlies tumor cell escape from virus‐specific T cell surveillance
31. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM‐1 and LFA‐1
32. Structure of glycoproteins and their oligosaccharide units
33. Mycophenolic acid and brequinar inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecular
34. VCAM‐1 on activated endothelium interacts with the leukocyte integrin VLA‐4 at a site distinct from the fibronectin binding site
35. PADGEM‐dependent adhesion of platelets to monocytes and neutrophils is mediated by lineage‐specific carbohydrate, LNFIII (CD15)
36. Carbohydrate ligands for endothelial leukocyte adhesion molecule 1
37. Lymphocyte‐selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice
38. Mycophenolic acid morpholinoethylester (RS‐61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T‐ and B‐cell purine synthesis
39. Cellular basis of skin graft rejection: an in vivo model of immune‐mediated tissue destruction
40. 51Cr‐labelled allogeneic target cells in vivo: inhibition by isoantibody and drugs
41. Plaque formation in agar by single antibody‐producing cells
42. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS‐61443) in rat and nonhuman primate recipients of heart allografts
43. RS‐61443, a new, potent immunosuppressive agent
44. RS‐61443 for reversal of acute rejection in canine renal allografts
45. 2‐Morpholino‐ethyl mycophenolic acid (ME‐MPA) in the treatment of refractory rheumatoid arthritis (RA)
46. RS‐61443—a phase I clinical trial and pilot rescue study
47. RS‐61443 (mycophenolate mofetil)
48. The later results of renal transplantation and the importance of chronic rejection as a cause of graft loss
49. Heart graft atherosclerosis
50. Chronic rejection graft arteriosclerosis
51. Graft coronary disease: the lesions and the patients
52. Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid, or deoxyspergaulin on vascular muscle proliferation in vitro and in vivo
53. Effects of immunosuppressive therapy in the rat aortic allograft model
54. Spectrum of vascular changes in primate cardiac xenografts
55. Epstein‐Barr virus (EBV)‐induced polyclonal B‐cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathological and virologic findings and implications for therapy
56. Chromosomal translations in lymphoid malignancies reveal novel protooncogenes
57. Action of bredinin on mammalian cells
58. Antipurines and purine metabolism
59. Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin
60. Maintenance immunosuppression with prednisolone and RS‐61443 alone following liver transplantation